Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier


     We are very grateful for the support of Brandcast media to produce this web stream
    VEP Soverini







    Mutation Screening:
    What is standard of care today and the role of new modalities
    Simona Soverini, University of Bologna, Italy 

    • BCR-ABL kinase domain (KD) mutation for optimal patient management
    • When to perform BCR-ABL KD mutation analysis
    • How to perform BCR-ABL KD mutation analysis
    • BCR-ABL KD mutation screening: key issues
    • Next-generation sequencing (NGS): applications
    • NGS for routine BCR-ABL mutatation testing: when?
    • NGS for routine BCR-ABL mutation screening: hurdles
    • Conclusions